ExploreWatchlistsPricing
  1. JP-listed companies
  2. SEIKAGAKU CORPORATION
  3. Financials
  4. Stockholders' equity

SEIKAGAKU CORPORATION (4548)

Market cap
¥42.8B
P/E ratio
45.7x
Develops and manufactures pharmaceuticals for joint care, eye surgery, and spinal treatments, plus specialized LAL testing reagents that ensure drug safety.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndStockholders' equity (Million JPY)YoY (%)
Mar 31, 202573,187+1.25%
Mar 31, 202472,282+7.54%
Mar 31, 202367,216+1.32%
Mar 31, 202266,340+4.30%
Mar 31, 202163,604+6.42%
Mar 31, 202059,767-18.17%
Mar 31, 201973,036-1.23%
Mar 31, 201873,945+4.67%
Mar 31, 201770,646+1.19%
Mar 31, 201669,815-0.85%
Mar 31, 201570,410+8.68%
Mar 31, 201464,785

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat